Novo Nordisk is among global pharma leaders in the diabetes and weight loss segments, with indicators of continued demand and sales growth. The firm's profit margin and expected EPS growth beats ...

Novo Nordisk is cutting a lot of deals with small biotechs. The latest deal seeks to develop gene-editing therapies, perhaps for obesity. These new types of therapies could be more economical than ...

Novo Nordisk (NVO) (OTCPK:NONOF) ADRs traded higher in the premarket on Wednesday after the Danish drugmaker released full ...

Novo Nordisk plans to file a label expansion for Rybelsus (oral semaglutide) as an adjunct treatment for the prevention of major adverse cardiovascular events (MACE) in patients with type 2 ...

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity ...

Bernie Sanders called "outrageously high" prices for the drugs. Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee ...

The European Commission has granted marketing authorisation for Novo Nordisk’s adult diabetes treatments Tresiba and Ryzodeg. The approval covers all 27 European Union member states. Tresiba ...

It's in Novo Nordisk's best interest to produce more winning cardiometabolic drugs. To that end, it's inking collaboration deals with multiple early-stage biotechs. Genetic medicines appear to be ...

Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s ...

Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week. Wegovy has been FDA-approved ...

The chief executive of the drugmaker Novo Nordisk, Lars Fruergaard Jørgensen, is scheduled to face tough questions Tuesday on Capitol Hill about the high costs of the company’s widely popular w ...